September 25, 2017 11:33 AM ET


Company Overview of Enumeral Biomedical Holdings, Inc.

Company Overview

Enumeral Biomedical Holdings, Inc., a biopharmaceutical company, engages in discovering and developing antibody immunotherapies that help the immune system fight cancer and other diseases. It is developing two antagonist PD-1 antibodies, such as ENUM 388D4 and ENUM 244C8 for use in treating cancer. The company is also developing antibody drug candidates for various immunomodulatory protein targets, including TIM-3, CD39, and TIGIT. Enumeral Biomedical Holdings, Inc. has collaboration agreements with Merck Sharp & Dohme Corp.; and The University of Texas MD Anderson Cancer Center, as well as a research contract with the National Cancer Institute. Enumeral Biomedical Holdings, Inc. was founded...

200 CambridgePark Drive

Suite 2000

Cambridge, MA 02140

United States

Founded in 2009



Key Executives for Enumeral Biomedical Holdings, Inc.

Interim CEO, Interim President, VP of Finance, Chief Accounting Officer, Treasurer & Director
Age: 52
Total Annual Compensation: $310.0K
Compensation as of Fiscal Year 2016.

Enumeral Biomedical Holdings, Inc. Key Developments

Enumeral Biomedical Holdings Receives An OTCQB Bid Price Deficiency Notice From OTC Markets

On September 19, 2017, Enumeral Biomedical Holdings, Inc. (Company) received an OTCQB Bid Price Deficiency Notice from OTC Markets (Notice). The Notice stated that the Company’s bid price had closed below $0.01 for more than 30 consecutive calendar days and no longer met the Standards for Continued Eligibility for OTCQB as per the OTCQB Standards Section 2.3(2). The Notice also stated that pursuant to Section 4.1 of the OTCQB Standards, the Company is granted a cure period of 90 calendar days during which the minimum closing bid price for the Company’s common stock must be $0.01 or greater for ten consecutive trading days in order to continue trading on the OTCQB marketplace.

Enumeral Biomedical Holdings, Inc. Announces Resignation of Paul J. Sekhri as Director

On September 1, 2017, Paul J. Sekhri resigned from the Board of Directors of Enumeral Biomedical Holdings, Inc. Mr. Sekhri’s resignation was not the result of a disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

Enumeral Biomedical Holdings, Inc Announces Unaudited Consolidated Earnings Results for the Second Quarter Ended June 30, 2017

Enumeral Biomedical Holdings, Inc. announced unaudited consolidated earnings results for the second quarter ended June 30, 2017. For the quarter, the company reported total revenue was $189,741 against $1,498,972 a year ago. Loss from operations was $2,358,221 against $1,487,033 a year ago. Net loss before income taxes was $3,138,594 against $1,347,557 a year ago. Net loss was $3,138,594 against $1,347,557 a year ago. Basic & diluted net loss per common share was $0.02 against $0.03 a year ago. This decrease in revenue is primarily attributable to the company’s license agreement with Pieris Pharmaceuticals and its study agreement with Merck.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Private Placement
May 19, 2017

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Tax Management Inc United States
Bertelsmann AG Europe

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Enumeral Biomedical Holdings, Inc., please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at